Expertise in
11
conditions

Dr. Roohi R. Ismail-Khan

Oncology
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Expertise in
11
conditions
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roohi Ismail-Khan is an Oncologist in Tampa, Florida. Dr. Ismail-Khan is highly rated in 11 conditions, according to our data. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Paget Disease of the Breast, and Ovarian Carcinosarcoma. Dr. Ismail-Khan is currently accepting new patients.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Radiation, Drug
Study Drug: Nivolumab
Study Phase: Phase 1
Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer
Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer
Enrollment Status: Completed
Publish Date: August 17, 2025
Intervention Type: Biological
Study Drug: HER-2 pulsed Dendritic Cell Vaccine
Study Phase: Phase 1
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy
Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: December 04, 2020
Intervention Type: Biological, Diagnostic test
Study Phase: Early Phase 1
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 20, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

41 Total Publications

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Jonathan R. Strosberg
Oncology
Expertise in
19
conditions
Dr. Jonathan R. Strosberg
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Strosberg is an Oncologist in Tampa, Florida. Dr. Strosberg is highly rated in 19 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Liver Embolization, and Pancreaticoduodenectomy.

Expertise in
28
conditions
Dr. Eric Padron
Oncology | Hematology
Expertise in
28
conditions
Dr. Eric Padron
Oncology | Hematology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Padron is an Oncologist and a Hematologist in Tampa, Florida. Dr. Padron is highly rated in 28 conditions, according to our data. His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Padron is currently accepting new patients.

Alberto A. Chiappori
Expertise in
14
conditions
Dr. Alberto A. Chiappori
Oncology
Expertise in
14
conditions
Dr. Alberto A. Chiappori
Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alberto Chiappori is an Oncologist in Tampa, Florida. Dr. Chiappori is highly rated in 14 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Chiappori is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ismail-Khan's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile